Cipher Pharmaceuticals Inc
PHE
Company Profile
Business description
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
Contact
5750 Explorer Drive
Suite 404
MississaugaONL4W 0A9
CANT: +1 905 602-5840
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
43
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
Real estate share remains cheap despite losing airport legal battle.
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks
What happens if Tesla and SpaceX merge?
We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.10 | 29.10 | 0.32% |
| CAC 40 | 8,314.07 | 113.28 | 1.38% |
| DAX 40 | 24,501.53 | 291.82 | 1.21% |
| Dow JONES (US) | 51,017.00 | 168.25 | 0.33% |
| FTSE 100 | 10,436.01 | 132.13 | 1.28% |
| HKSE | 24,718.10 | 468.81 | 1.93% |
| NASDAQ | 25,683.13 | 126.53 | -0.49% |
| Nikkei 225 | 66,020.04 | 1,802.77 | 2.81% |
| NZX 50 Index | 13,393.87 | 191.71 | 1.45% |
| S&P 500 | 7,385.96 | 8.34 | -0.11% |
| S&P/ASX 200 | 8,804.00 | 30.50 | 0.35% |
| SSE Composite Index | 4,031.51 | 44.50 | 1.12% |